Cargando…
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response
INTRODUCTION: New generation biologics, including interleukin (IL)-17 and IL-23 inhibitors, have delivered higher rates of skin clearance than older treatments in head-to-head studies. However, studies comparing these new biologics directly to one another are limited. OBJECTIVES: To compare the shor...
Autores principales: | Sawyer, Laura M., Malottki, Kinga, Sabry-Grant, Celia, Yasmeen, Najeeda, Wright, Emily, Sohrt, Anne, Borg, Emma, Warren, Richard B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693782/ https://www.ncbi.nlm.nih.gov/pubmed/31412060 http://dx.doi.org/10.1371/journal.pone.0220868 |
Ejemplares similares
-
Assessing the Quality and Coherence of Network Meta-Analyses of Biologics in Plaque Psoriasis: What Does All This Evidence Synthesis Tell Us?
por: Wright, Emily, et al.
Publicado: (2020) -
The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain
por: Maravilla-Herrera, Paulina, et al.
Publicado: (2023) -
Long‐term efficacy of novel therapies in moderate‐to‐severe plaque psoriasis: a systematic review and network meta‐analysis of PASI response
por: Sawyer, L.M., et al.
Publicado: (2018) -
Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
por: Koutruba, Nora, et al.
Publicado: (2010) -
Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses
por: Baker, Erica L., et al.
Publicado: (2012)